TipRanks
Lytix Biopharma AS (DE:6BG)
FRANKFURT:6BG
Germany Market
6BG
Lytix Biopharma AS
RESEARCH TOOLSreports

Lytix Biopharma AS (6BG) Income Statement

3 Followers

Lytix Biopharma AS Income Statement

Last quarter (Q2 2026), Lytix Biopharma AS's total revenue was kr0.00, a decrease of ― from the same quarter last year. In Q2, Lytix Biopharma AS's net income was kr-26.67M. See Lytix Biopharma AS’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
kr 0.00kr 11.13Mkr 3.99Mkr 11.03Mkr 19.31M
Gross Profit
kr -1.00Mkr -23.46Mkr 3.99Mkr 11.03Mkr 19.31M
Operating Expenses
kr 67.65Mkr 77.17Mkr 100.78Mkr 76.70Mkr 67.29M
Depreciation and Amortization
kr 1.00Mkr 915.00Kkr 962.00Kkr 919.00Kkr 453.00K
EBITDA
kr -63.02Mkr -93.22Mkr -86.88Mkr -54.91Mkr -47.56M
Operating Income
kr -68.65Mkr -95.90Mkr -96.78Mkr -65.67Mkr -47.98M
Other Income/Expenses
kr 8.67Mkr 6.37Mkr 8.89Mkr 9.60Mkr -94.00K
Pretax Income
kr -59.98Mkr -94.27Mkr -87.90Mkr -56.07Mkr -48.08M
Net Income
kr -59.98Mkr -94.27Mkr -87.90Mkr -56.07Mkr -48.08M
Per Share Metrics
Basic EPS
kr -0.88kr -1.74kr -2.19kr -1.41kr -1.45
Diluted EPS
kr -0.88kr -1.74kr -2.19kr -1.41kr -1.45
Weighted Average Shares Outstanding
 68.53M 54.13M 40.07M 39.67M 38.74M
Weighted Average Shares Outstanding (Diluted)
 68.53M 54.13M 40.07M 39.67M 38.74M
Currency in NOK

Lytix Biopharma AS Earnings and Revenue History